The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Combination treatment with bemcentinib (BGB324) and pembrolizumab (Keytruda) in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer (NSCLC) was well tolerated and clinically active, according to updated results from the phase 2 BGBC008 clinical trial (NCT03185471) presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) Singapore.
In this single-arm, 2-stage study (NCT03184571), patients were treated with bemcentinib at a dose of 200mg per day and pembrolizumab at a dose of 200 mg every 3…
